302 related articles for article (PubMed ID: 37713432)
1. Tumor Abnormality-Oriented Nanomedicine Design.
Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
[TBL] [Abstract][Full Text] [Related]
2. Anticancer nanomedicines harnessing tumor microenvironmental components.
Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
4. Renal clearable nanocarriers: Overcoming the physiological barriers for precise drug delivery and clearance.
Peng C; Huang Y; Zheng J
J Control Release; 2020 Jun; 322():64-80. PubMed ID: 32194171
[TBL] [Abstract][Full Text] [Related]
5. Barrier permeation and improved nanomedicine delivery in tumor microenvironments.
Liu J; Zhang J; Gao Y; Jiang Y; Guan Z; Xie Y; Hu J; Chen J
Cancer Lett; 2023 May; 562():216166. PubMed ID: 37028698
[TBL] [Abstract][Full Text] [Related]
6. Polysaccharide-Based Stimulus-Responsive Nanomedicines for Combination Cancer Immunotherapy.
Li Q; Liu X; Yan C; Zhao B; Zhao Y; Yang L; Shi M; Yu H; Li X; Luo K
Small; 2023 Jun; 19(23):e2206211. PubMed ID: 36890780
[TBL] [Abstract][Full Text] [Related]
7. Combined cancer therapeutics-Tackling the complexity of the tumor microenvironment.
Roma-Rodrigues C; Raposo LR; Valente R; Fernandes AR; Baptista PV
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1704. PubMed ID: 33565269
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeted nanomedicines for cancer theranostics.
Arranja AG; Pathak V; Lammers T; Shi Y
Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
[TBL] [Abstract][Full Text] [Related]
9. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
[TBL] [Abstract][Full Text] [Related]
10. Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy.
Jia R; Teng L; Gao L; Su T; Fu L; Qiu Z; Bi Y
Int J Nanomedicine; 2021; 16():1525-1551. PubMed ID: 33658782
[TBL] [Abstract][Full Text] [Related]
11. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
[TBL] [Abstract][Full Text] [Related]
13. Platinum-based combination nanomedicines for cancer therapy.
Li Y; Lin W
Curr Opin Chem Biol; 2023 Jun; 74():102290. PubMed ID: 36989943
[TBL] [Abstract][Full Text] [Related]
14. Boosting Nanomedicine Efficacy with Hyperbaric Oxygen Therapy.
Wang X; Li S; Liu X; Wu X; Ye N; Yang X; Li Z
Adv Exp Med Biol; 2021; 1295():77-95. PubMed ID: 33543456
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in dual- and multi-responsive nanomedicines for precision cancer therapy.
Zhang Y; Li J; Pu K
Biomaterials; 2022 Dec; 291():121906. PubMed ID: 36395660
[TBL] [Abstract][Full Text] [Related]
16. Stimuli-responsive polypeptide nanoassemblies: Recent progress and applications in cancer nanomedicine.
Song Y; Ding Y; Dong CM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Mar; 14(2):e1742. PubMed ID: 34310063
[TBL] [Abstract][Full Text] [Related]
17. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
18. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D; Zhou S; Gao W
ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
[TBL] [Abstract][Full Text] [Related]
19. Modulating tumor mechanics with nanomedicine for cancer therapy.
Zhao Q; Chen J; Zhang Z; Xiao C; Zeng H; Xu C; Yang X; Li Z
Biomater Sci; 2023 Jun; 11(13):4471-4489. PubMed ID: 37221958
[TBL] [Abstract][Full Text] [Related]
20. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
